These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28198434)

  • 1. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
    Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
    Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
    Chang AY; Zhou YJ; Iyengar S; Pobiarzyn PW; Tishchenko P; Shah KM; Wheeler H; Wang YM; Loria PM; Loganzo F; Woo SR
    J Biol Chem; 2021 Nov; 297(5):101277. PubMed ID: 34619148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pre-mRNA splicing and transcription factor Tat-SF1 is a functional partner of the spliceosome SF3b1 subunit via a U2AF homology motif interface.
    Loerch S; Leach JR; Horner SW; Maji D; Jenkins JL; Pulvino MJ; Kielkopf CL
    J Biol Chem; 2019 Feb; 294(8):2892-2902. PubMed ID: 30567737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Spliceosome Inhibition in SF3B1-Mutated Uveal Melanoma.
    Nguyen JQN; Drabarek W; Leeflang AMCHJ; Brands T; van den Bosch TPP; Verdijk RM; van de Werken HJG; van Riet J; Paridaens D; de Klein A; Brosens E; Kiliç E;
    Invest Ophthalmol Vis Sci; 2024 Oct; 65(12):11. PubMed ID: 39374010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
    Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
    Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
    Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
    RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
    Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research.
    Samy A; Ozdemir MK; Alhajj R
    Sci Rep; 2023 Feb; 13(1):2704. PubMed ID: 36792691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
    Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
    Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
    Kim Guisbert KS; Guisbert E
    PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.
    Maji D; Grossfield A; Kielkopf CL
    Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194440. PubMed ID: 31707043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
    López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
    Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.
    Jorge J; Petronilho S; Alves R; Coucelo M; Gonçalves AC; Nascimento Costa JM; Sarmento-Ribeiro AB
    Invest New Drugs; 2020 Apr; 38(2):369-377. PubMed ID: 31147807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1.
    Hluchý M; Gajdušková P; Ruiz de Los Mozos I; Rájecký M; Kluge M; Berger BT; Slabá Z; Potěšil D; Weiß E; Ule J; Zdráhal Z; Knapp S; Paruch K; Friedel CC; Blazek D
    Nature; 2022 Sep; 609(7928):829-834. PubMed ID: 36104565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.